For a cancer vaccine to be effective, it should ideally deliver the concentrated antigen to both HLA class I and class II molecules in DCs, thereby facilitating responses from both CD4+ and CD8+ T cells.243, 244. The gene discussed is CD8A; the disease is cancer.